Novel First-Trimester Prediction Model for Any Type of Preterm Birth Occurring before 37 Gestational Weeks in the Absence of Other Pregnancy-Related Complications Based on Cardiovascular Disease-Associated MicroRNAs and Basic Maternal Clinical Characteristics.
cardiovascular microRNAs
early gestation
expression
peripheral venous blood
prediction
preterm delivery
preterm prelabor rupture of membranes
screening
spontaneous preterm birth
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
15 Oct 2022
15 Oct 2022
Historique:
received:
16
08
2022
revised:
06
10
2022
accepted:
12
10
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
The goal of the study was to establish an efficient first-trimester predictive model for any type of preterm birth before 37 gestational weeks (spontaneous preterm birth (PTB) or preterm prelabor rupture of membranes (PPROM)) in the absence of other pregnancy-related complications, such as gestational hypertension, preeclampsia, fetal growth restriction, or small for gestational age. The retrospective study was performed in the period from 11/2012 to 3/2020. Peripheral blood samples were collected from 6440 Caucasian individuals involving 41 PTB and 65 PPROM singleton pregnancies. A control group with 80 singleton term pregnancies was selected on the basis of equal sample-storage time. A combination of only six microRNAs (miR-16-5p, miR-21-5p, miR-24-3p, miR-133a-3p, miR-155-5p, and miR-210-3p; AUC 0.812, p < 0.001, 70.75% sensitivity, 78.75% specificity, cut-off > 0.652) could predict preterm delivery before 37 gestational weeks in early stages of gestation in 52.83% of pregnancies with a 10.0% FPR. This predictive model for preterm birth based on aberrant microRNA expression profile was further improved via implementation of maternal clinical characteristics (maternal age and BMI at early stages of gestation, infertility treatment with assisted reproductive technology, occurrence of preterm delivery before 37 gestational weeks in previous pregnancy(ies), and presence of any kind of autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, type 1 diabetes mellitus, or other autoimmune disease)). With this model, 69.81% of pregnancies destined to deliver before 37 gestational weeks were identified with a 10.0% FPR at early stages of gestation. When other clinical variables as well as those mentioned above—such as positive first-trimester screening for early preeclampsia with onset before 34 gestational weeks and/or fetal growth restriction with onset before 37 gestational weeks using the Fetal Medicine Foundation algorithm, as well as positive first-trimester screening for spontaneous preterm birth with onset before 34 gestational weeks using the Fetal Medicine Foundation algorithm—were added to the predictive model for preterm birth, the predictive power was even slightly increased to 71.70% with a 10.0% FPR. Nevertheless, we prefer to keep the first-trimester screening for any type of preterm birth occurring before 37 gestational weeks in the absence of other pregnancy-related complications as simple as possible.
Identifiants
pubmed: 36289853
pii: biomedicines10102591
doi: 10.3390/biomedicines10102591
pmc: PMC9599357
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Charles University
ID : Cooperatio - Mother and Childhood Care no. 207035
Organisme : Charles University
ID : SVV no. 260529
Références
Ultrasound Obstet Gynecol. 2017 Jun;49(6):756-760
pubmed: 28295782
PLoS One. 2012;7(2):e31136
pubmed: 22348044
Thromb Res. 2016 Jan;137:126-140
pubmed: 26632513
J Reprod Immunol. 2011 Mar;88(2):176-84
pubmed: 21236496
Int J Mol Sci. 2022 Apr 01;23(7):
pubmed: 35409311
Prenat Diagn. 2011 Jan;31(1):75-83
pubmed: 21210482
J Pers Med. 2021 Jan 11;11(1):
pubmed: 33440716
Obstet Gynecol. 2018 Jul;132(1):e44-e52
pubmed: 29939940
Am J Obstet Gynecol. 2016 Jan;214(1):103.e1-103.e12
pubmed: 26297382
Lancet. 1980 Jan 26;1(8161):192-4
pubmed: 6101643
Reprod Sci. 2011 Aug;18(8):781-97
pubmed: 21795739
J Clin Endocrinol Metab. 2003 May;88(5):2194-205
pubmed: 12727975
Int J Mol Sci. 2020 Mar 31;21(7):
pubmed: 32244558
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
Reprod Sci. 2009 Feb;16(2):206-15
pubmed: 19208789
Ultrasound Obstet Gynecol. 2018 Aug;52(2):186-195
pubmed: 29896812
Int J Epidemiol. 1993 Jun;22(3):495-503
pubmed: 8359967
Int J Mol Sci. 2022 Sep 13;23(18):
pubmed: 36142536
Am J Pathol. 2014 Jun;184(6):1740-51
pubmed: 24832021
BJOG. 2006 Dec;113 Suppl 3:17-42
pubmed: 17206962
Am J Perinatol. 1990 Oct;7(4):374-9
pubmed: 2222633
Ultrasound Obstet Gynecol. 2020 Sep;56(3):400-407
pubmed: 32441401
Int J Cardiol. 2019 Sep 15;291:158-167
pubmed: 31151766
Biomedicines. 2022 Jan 25;10(2):
pubmed: 35203467
Biomedicines. 2022 Mar 19;10(3):
pubmed: 35327520
Front Immunol. 2018 May 09;9:993
pubmed: 29867970
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Am J Reprod Immunol. 2014 Jul;72(1):75-84
pubmed: 24589083
Lancet. 2008 Jan 5;371(9606):75-84
pubmed: 18177778
Am J Obstet Gynecol. 1995 Oct;173(4):1310-5
pubmed: 7485344